Skip to content

Xencor XNCR Additional Paid-In Capital

Additional Paid-In Capital at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$14.4B+9.2%
Janux Therapeutics logo
Janux TherapeuticsJANX
$1.32B+3.7%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$196.62M+16.6%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$838.31M+0.7%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$264.88M+27.1%
Absci Corporation logo
Absci CorporationABSI
$826.04M+12.4%

Other financials

Income statement

See full
Revenue$4.5M-86.2%
Operating income-$77.9M-80.3%
Net income-$128.9M-166%
EPS (diluted)-$1.71-159%

Balance sheet

See full
Cash & equivalents$14.2M-64.3%
Total debt$175.2M-21.2%
Total equity$515.6M-19.4%
Total assets$736.8M-18.6%

Cash flow

See full
Operating cash flow-$67.6M-317%
CapEx$610.0K-57.8%
Free cash flow-$68.2M-286%

Valuation

See full
Market cap$1.07B+76.3%
Enterprise value$1.23B+55.9%
P/S11×+6.2×

Profitability

See full
Operating margin-217.9%+425pp
Net margin-177.1%+16.5pp
FCF margin-194%+166pp

Returns & leverage

See full
Return on equity-29.8%-2.7pp
Debt / equity0.3×0.0×
Current ratio6.6×+0.7×

Where this comes from

Reported directly by Xencor in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.

The official record: Xencor’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Xencor's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Xencor's additional paid-in capital?
Xencor (XNCR) reported additional paid-in capital of $1.44B in Q1 2026.
How has Xencor's additional paid-in capital changed year-over-year?
Xencor's additional paid-in capital increased by 3.5% year-over-year, from $1.39B to $1.44B.
What is the long-term trend for Xencor's additional paid-in capital?
Over 5 years (2020 to 2025), Xencor's additional paid-in capital has grown at a 8.8% compound annual growth rate (CAGR), from $937.53M to $1.43B.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.